Corona Remedies IPO — Date, Price Band, GMP & Allotment 2025

Corona Remedies Limited is an Indian pharmaceutical company established in 2004, focused on developing and marketing a wide range of branded formulations. The company was founded by Chandrakant Patel, who brought extensive experience from the domestic pharma industry. Over the years, Corona Remedies has built a strong presence in therapeutic segments such as women’s healthcare, cardiology, diabetology, pain management and anti-infectives. The company operates with a customer-centric approach, emphasising quality, innovation and accessibility of medicines. It has developed a robust distribution network across India, supported by a large field force that engages with healthcare professionals and institutions. By focusing on niche and high-growth segments, the company has been able to strengthen its brand recall and expand its footprint in the competitive pharmaceutical market.

The company’s product portfolio consists primarily of branded generic medicines, including tablets, capsules, syrups and injectables, catering to both acute and chronic therapies. Corona Remedies follows an asset-light business model, where manufacturing is largely outsourced to WHO-GMP certified third-party facilities while it focuses on marketing, branding and distribution. This allows the company to maintain flexibility and control costs while ensuring consistent product quality. Its strategy revolves around launching differentiated products, building strong doctor relationships and expanding into new therapeutic areas. With a steady focus on research-backed marketing and efficient supply chain management, Corona Remedies aims to sustain long-term growth and strengthen its position in the Indian pharmaceutical industry.

Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.

The Corona Remedies company's financial performance (in ₹ Cr.) is summarized below:

See how this IPO compares — view listing performance of all mainboard IPOs.